Cilengitide

As a class of specific bioactive molecules with targeted regulatory potential, Cilengitide's efficacy is highly focused on two core dimensions: blocking and regulating neoplastic lesion invasion and dissemination, and precise intervention in ocular pathological lesions. Together, they constitute the core direction of its clinical research and application exploration. Compared with traditional intervention formulations that often present a single target and single pathway mode of action, this molecule relies on its unique circular peptide chain structure to endow it with targeted affinity characteristics, which can accurately identify and bind to specific targets. It exhibits exclusive advantages in inhibiting neoplasm cell invasion and migration across tissues, limiting malignant spread of lesions, and alleviating related lesions caused by abnormal neovascularization in the eye, which are different from conventional formulations. Its precision and specificity not only effectively improve the intervention effect, but also reduce the potential impact of non-specific effects.

 

Our Products Description

 

​

Cilengitide COA

Certificate of Analysis
Compound name	Cilengitide
Grade	Pharmaceutical grade
CAS No.	188968-51-6
Quantity	38g
Packaging standard	PE bag+Al foil bag
Manufacturer	Shaanxi BLOOM TECH Co., Ltd
Lot No.	202601090078
MFG	Jan 9th 2026
EXP	Jan 8th 2029
Structure
Item	Enterprise standard	Analysis result
Appearance	White or almost white powder	Conformed
Water content	≤5.0%	0.54%
Loss on drying	≤1.0%	0.42%
Heavy Metals	Pb≤0.5ppm	N.D.
	As≤0.5ppm	N.D.
	Hg≤0.5ppm	N.D.
	Cd≤0.5ppm	N.D.
Purity (HPLC)	≥99.0%	99.98%
Single impurity	<0.8%	0.52%
Total microbial count	≤750cfu/g	95
E. Coli	≤2MPN/g	N.D.
Salmonella	N.D.	N.D.
Ethanol (by GC)	≤5000ppm	500ppm
Storage	Store in a sealed, dark, and dry place below -20°C

The blocking and diffusion limiting effects of this med on neoplasm infiltration and metastasis

The core crux of neoplastic lesion infiltration and metastasis lies in the breakthrough of lesion cells through tissue barriers and the realization of cross site colonization. It forms a three-dimensional blockade of this process through multi link regulation, and its characteristics of strong targeting and comprehensive intervention can be carried out from the following aspects:

(I)Interference with the adhesion and colonization ability of lesion cells.
The infiltration of neoplastic lesion cells first relies on their adhesion and binding to the surrounding matrix, and this binding process requires the mutual recognition of specific receptors and ligands. Cilengitide can competitively bind to relevant receptor sites, block the affinity between lesion cells and extracellular matrix components, weaken the anchoring ability of cells, and reduce the possibility of neoplasm cells detaching from the primary lesion from the source, laying the foundation for blocking infiltration and metastasis. Related studies have shown that in various solid neoplastic lesion models, this molecule can significantly reduce the adhesion efficiency between lesion cells and matrix, and reduce the occurrence of cell shedding.

Inhibit mobility

(II)The migration ability of tumor cells is the key to achieving distant spread, and this process is regulated by intracellular signaling pathways.

This can inhibit the motility of lesion cells, reduce the migration rate of cells, prevent their infiltration into surrounding normal tissues, and limit their entry into blood circulation, lymphatic circulation, and other diffusion pathways by regulating the activity of related signaling pathways, thereby reducing the formation of distant metastases. In cell experiments of ovarian cancer, breast cancer and other solid neoplastic lesion, this molecule can significantly inhibit the migration ability of neoplasm cells and narrow the migration range.

(III)Regulating the pro metastatic properties of tumor microenvironment.
The relevant cells and factors in the neoplastic lesion microenvironment provide support for neoplasm infiltration and metastasis, and it can reverse its pro metastatic tendency by regulating the expression of relevant components in the microenvironment. For example, it can inhibit the secretion of pro metastatic factors by cancer-related fibroblasts, reduce abnormal remodeling of the extracellular matrix, disrupt the microenvironmental conditions required for neoplastic lesion infiltration and metastasis, further strengthen the limiting effect on tumor spread, and form a dual intervention effect of "blocking the cell's own ability+regulating the microenvironment".

The information in this chapter comes from:

Zhu F, Yuan S, Li J, et al. this peptide Inhibits Neovascularization in a Rabbit Abdominal Aortic Plaque Model by Impairing the VEGF Signaling. Biomed Res Int, 2021, 2021:5954757.
Xiang Peng, Yang Yang Combination inhibition of surface CD51 and gamma secretase mediated CD51 cleavage improves the therapeutic effect of experimental metastatic liver cancer [J]. Chinese Journal of Hepatology, 2024, 32 (2): 189-196

Application characteristics and anti angiogenic effects of it in ophthalmic diseases

In ophthalmic diseases, the core application of this focuses on the intervention of wet age-related macular degeneration. Its core function is to inhibit the formation of abnormal neovascularization in the eye, alleviate disease progression, and protect visual function. Its characteristics of action are both targeted and safe. The specific analysis is as follows:

Accurately targeting abnormal neovascularization in the eye
The core pathological change of wet age-related macular degeneration is the abnormal proliferation of choroidal neovascularization, which is structurally fragile and prone to leakage, leading to macular edema, bleeding, and ultimately damaging visual function. This can specifically act on the relevant receptors on the surface of endothelial cells in new blood vessels, block the binding of receptors and ligands, inhibit the proliferation, migration, and lumen formation of endothelial cells, thereby preventing the growth of abnormal new blood vessels, alleviating pathological progression, and avoiding further damage to visual function.

Intervention has organizational specificity
The physiological structure of eye tissues is unique, and high specificity is required for intervention agents. Cilengitide can selectively act on abnormal neovascularization in the eye, without significant effects on normal eye blood vessels and tissue cells. It can effectively avoid damage to normal eye physiological functions caused by intervention and reduce the risk of adverse reactions. This feature makes it significantly advantageous in ophthalmic disease intervention, and compared to non-specific anti angiogenic agents, its safety is more guaranteed.

Collaborative relief of symptoms related to lesions

Patients with wet age-related macular degeneration frequently present with typical clinical manifestations including macular edema, exudation, and hemorrhage, which seriously damage retinal structure and further lead to significant visual function impairment. The drug can effectively inhibit the formation of abnormal choroidal neovascularization, indirectly reduce vascular permeability and leakage, relieve retinal edema, and mitigate exudative lesions.

By improving the microenvironment of the macular region, it significantly enhances the visual acuity and quality of life of patients. Furthermore, its therapeutic effect is stable and long‑lasting, which can continuously suppress neovascular growth, delay the progression of pathological changes, and provide sustained and reliable protection for the long-term maintenance of patients' visual function.

The information in this chapter comes from:

Zhang Y, Li L, Wang H. Targeted inhibition of integrin αVβ3 by peptide suppresses ovarian cancer cell migration and spheroid formation. Int J Oncol, 2023, 62(3):112.

Li J, Wang Y, Chen F. peptide combined with trastuzumab overcomes trastuzumab resistance in HER2-positive breast cancer by targeting ITGB3 heterogeneity. Biol, 2025, 14(1):9.

In summary, it is not difficult to see from the detailed analysis of multiple dimensions in the previous text that Cilengitide has demonstrated irreplaceable unique value in the two core application scenarios of blocking and regulating neoplastic lesion infiltration and metastasis, and anti angiogenic therapy for wet age-related macular degeneration. Its core advantages run through the entire process of action mechanism, intervention effect, and application safety. The distinctive characteristics of this molecule, such as strong targeting, precise intervention, and good safety, make it different from traditional intervention preparations and become a highly potential core molecule in the current field of disease intervention research, providing important material and theoretical support for clinical research and subsequent application exploration. Specifically, at the level of neoplasm intervention, it constructs a three-dimensional blockade system for tumor infiltration and metastasis by interfering with the adhesion of lesion cells, inhibiting cell migration, and regulating the neoplasm microenvironment, effectively limiting the malignant spread of lesions and providing a differentiated technical path for precise neoplasm intervention.

At the level of ophthalmic disease intervention, it relies on precise targeting of abnormal neovascularization in the eye, while inhibiting abnormal vascular proliferation, synergistically alleviating accompanying symptoms such as macular edema and exudation, maximizing the protection of patients' visual function, and without significant damage to normal eye tissues, significantly improving the safety and effectiveness of intervention. Whether it is the multi link and multi-target limitation of neoplastic lesion spread, or the specific inhibition of abnormal neovascularization in the eye, this breaks the limitations of traditional intervention models, providing new ideas and directions for the treatment of related diseases, and also providing important references for the optimization of clinical treatment plans. With the continuous deepening of related basic research and clinical trials, its mechanism of action will be further clarified, and its application scenarios will be further expanded. Its potential application value is expected to be fully explored and released, bringing new treatment hope to more patients with related diseases.

The information in this chapter comes from:

Wang Min, Li Li, Zhang Tao The inhibitory effect of peptide on choroidal neovascularization in a mouse model of wet age-related macular degeneration [J]. New Advances in Ophthalmology, 2024, 44 (5): 361-365

References

Peterson A, Smith J, Jones C. Anti-integrin therapy with peptide for retinovascular diseases: preclinical evidence and future perspectives. J Ocul Pharmacol Ther, 2023, 39(4):289-298.

Zhao H, Liu Z, Zhang L. this inhibits neoplastic lesion invasion by regulating the CD51-ICD/OXPHOS axis in hepatocellular carcinoma. J Hepatol, 2023, 79(2):287-299.

Schmidt M, Mü ller K, Weber S. peptide as a potential therapeutic agent for wet age-related macular degeneration: a preclinical study. Graefes Arch Clin Exp Ophthalmol, 2022, 250(11):1879-1888.

Chen W, Li M, Zhang H. The role of peptide in inhibiting neoplasm metastasis by modulating the tumor microenvironment. Cancer Biol Ther, 2024, 25(3):189-198.

Hot Tags: cilengitide, China cilengitide manufacturers, suppliers